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ABSTRACT
To be effective in vivo, antisense oligonucleotides
(AS ON) should be nuclease resistant, form stable
ON/RNA duplexes and support ribonuclease H
mediated heteroduplex cleavage, all with negligible
non-specificeffectsoncellfunction.Wereportherein
that AS ONs containing a 20-deoxy-20-fluoro-b-D-
arabinonucleic acid (20F-ANA) sugar modification
not only meet these criteria, but have the added
advantage of maintaining high intracellular concen-
trations for prolonged periods of time which appears
to promote longer term gene silencing. To demon-
strate this, we targeted the c-MYB protooncogene’s
mRNA in human leukemia cells with fully phos-
phorothioated 20F-ANA–DNA chimeras (PS-20FANA–
DNA) and compared their gene silencing efficiency
with AS ON containing unmodified nucleosides
(PS-DNA). When delivered by nucleofection, che-
mically modified ON of both types effected a .90%
knockdown of c-MYB mRNA and protein expression,
but the PS-20F-ANA–DNA were able to accomplish
this at 20% of the dose of the PS-DNA, and in contrast
to the PS-AS DNA, their silencing effect was still
present after 4 days after a single administration.
Therefore, our data demonstrate that PS-20F-ANA–
DNA chimeras are efficient gene silencing mole-
cules, and suggest that they could have significant
therapeutic potential.
INTRODUCTION
There has been an explosive resurgence of interest in thera-
peutically motivated gene silencing since the discovery that
RNA interference may be effected in mammalian cells with
short interfering RNA (siRNA) molecules (1,2). At the
same time, it has become clear that many of the issues that
determine the efﬁciency of more traditional gene silencing
molecules such as antisense oligodeoxynucleotides (AS
ODN) and ribozymes will also pertain to siRNA molecules.
These include appropriate mRNA target selection, effective
delivery into cells expressing the target gene, proper selection
of nucleotide sequence to target within the mRNA of interest
and molecule stability (3–7). It has also become apparent
that effectively delivered and rationally targeted AS ODN
can silence gene expression as efﬁciently as the best siRNA
molecules (8). These observations, combined with the fact
that DNA molecules are generally easier and less expensive
to synthesize in bulk than RNA molecules, has sustained the
ﬁeld of therapeutic gene targeting with antisense oligonuc-
leotides (AS ON).
Our group has been particularly interested in the issues of
therapeutic target gene selection, mRNA sequence selection
for targeting (9) and with chemical modiﬁcations of ODN
that yield enhanced antisense effects (10,11). Such chemical
modiﬁcations are ideally thought to enhance ODN hybridiza-
tion to the selected nucleotide sequence within the targeted
mRNA, permit ribonuclease H (RNase H) binding to the
ODN/mRNA heteroduplex so that mRNA cleavage can fol-
low, and enhance ODN stability to exo and endonucleases so
that intracellular dwell time is increased once the molecules
are delivered.
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doi:10.1093/nar/gkj455A very large number of chemical modiﬁcations have been
made to ODN in order to enhance their stability, and raise the
melting temperature (Tm) of mRNA hybrids once formed. To a
great extent, these modiﬁcations have focused on the ribose
sugar and the internucleotide linkage group (2,5,7,12,13).
With regard to the latter, arguably the most successful, and
still widely employed, is the phosphorothioate modiﬁcation
originally synthesized by Eckstein (14,15). Here, one of the
non-bridging oxygen atoms in the internucleoside phosphate
group is replaced with a sulfur atom creating the phos-
phorothioate (PS) modiﬁcation of ODN (PS-DNA). When
compared with natural DNA, PS-DNA is moderately nuclease
resistant and retains the ability to activate RNase H. However,
these desirable properties are offset by the fact that the PS
modiﬁcation lowers the Tm of ODN/mRNA heteroduplexes,
and the sulfur atom promotes non-speciﬁc binding to many
intra- and extracellular proteins (16–18). Unintended, and at
times undesirable, biological side effects can be observed as
a result (14,19,20).
Many chemical modiﬁcations have been developed to
enhance the gene silencing properties of PS-DNA molecules.
A typical strategy is to ﬂank a central core of PS-DNA with
nucleotides modiﬁed to promote enhanced nuclease resist-
ance, and to raise the Tm of resulting heteroduplexes. The
most promising of these are 20-O-alkyl modiﬁcations such
as the 20-O-methyl and 20-O-methoxyethyl groups (21,22).
These substitutions confer an RNA-like (north or C30-endo)
conformation to the ONs which has the beneﬁcial effect of
raising the Tm of formed heteroduplexes, but unfortunately,
this enhanced stability is achieved at the expense of RNase H
activation. Since RNase H activation is critical for effective
antisense activity in living cells (11), this latter characteristic
is highly undesirable.
A recently described 20-deoxy-20-ﬂuoro-b-D-arabinonucleic
acid (20F-ANA) analog appears to overcome this important
disadvantage of the 20-O-alkyl modiﬁed gapmer molecules.
ANA is a 20-stereoisomer of RNA based on D-arabinose
(23). When the ANA is further modiﬁed by substitution of
the 20-OH group with a ﬂuorine atom, the 20F-ANA is created
(24) (Figure 1). The 20F-ANA has signiﬁcantly enhanced bind-
ing afﬁnity to the target mRNA compared with native or PS
modiﬁed DNA (25,26). Remarkably, and importantly, 20F-
ANA/RNA duplexes, unlike 20F-RNA/RNA duplexes retain
the ability to activate RNase H (11,26). This is because
20F-ANA/RNA duplexes are structurally similar to normal
DNA/RNA duplexes (27,28). At the same time, because the
20F-substituent in 20F-ANA/RNA hybrids projects into the
major groove of the helix, it does not signiﬁcantly interfere
with the binding and subsequent catalysis of RNA by RNase H
(19,29). Indeed, incorporation of DNA into the 20F-ANA
structure accelerates RNase H mediated RNA cleavage to a
level that is superior to that observed with PS-DNA (11). For
example, we have reported that PS-20F-ANA–DNA chimeras
consisting of a core of six DNA nucleotides ﬂanked by
20F-ANA wings resulted in an AS ON with high-afﬁnity
RNA binding, excellent RNase H cleavage properties
and gene silencing efﬁcacy in the low nanomolar range
(<10 nM) (11). Herein we report studies which directly com-
pare the gene silencing efﬁciency of two different designs
of PS-20F-ANA–DNA chimeric molecules and PS-DNA
molecules. Our results indicate that the 20F-ANA-containing
ON with central, or alternating, stretches of PS-DNA had
greater potency, and duration of action, than those exhibited
by ON composed solely of PS-DNA.
MATERIALS AND METHODS
ODN synthesis
Unmodiﬁed phosphorothioate ODNs were synthesized by
Integrated DNA Technology (IDT, Coralville). PS-20F-
ANA–DNA chimeras were synthesized in the Department
of Chemistry (McGill University, Montreal, QC, Canada)
using a previously reported methodology (30). The sequences
of ODNs employed in this study are described in Table 1.
Cell culture and transfection
K562 cells were cultured in RPMI medium supplemented
with 10% of fetal bovine serum (FBS) and 0.5% penicillin/
streptomycin at 37 C in a humidiﬁed incubator (95%
humidity) and 5% CO2. Culture media was changed every
second day or as required by rapidity of cell growth.
Figure 1. Chemical structure of 20F-ANA compared with RNA and ANA.
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+ cells were cultured in IMDM medium
supplemented with 2% FBS and 0.5% penicillin/streptomycin.
Cells were transfected with ODN using an Amaxa nucleo-
fector (Amaxa Inc., Gaithersburg) as reported previously (10).
In brief, 3 · 10
6 cells were washed two times in phosphate-
buffered saline (PBS), and then suspended in 100 ml of nuc-
leofection solution supplied by the manufacturer containing
5 mg of ODN (ﬁnal concentration ¼ 7.9 mM). For dose
response studies, concentrations of 1 and 0.5 mg of ODN
were used as well. Immediately after nucleofection, the cell
suspension was moved into 5 ml of culture medium and
maintained in 6-well plates for 24, 72 and 96 h.
Quantitative real-time PCR (QRT-PCR)
Total RNA was isolated from cells harvested after 24, 72 and
96 h using an RNeasy mini Kit (Qiagen Scientiﬁcs, MD)
according to the manufacturer’s instructions. Reverse tran-
scription was carried out with an Iscript reverse transcription
kit (BioRad, Hercules, CA). The resulting cDNA was used as a
template for QRT-PCR, which was performed using TaqMan
Universal PCR Master Mix (Applied Biosystems, Foster
City, CA) and iCycler iQ Real-Time PCR Detection System
(BioRad).
For c-MYB PCR the following primers were used: forward,
dGAAGGTCGAACAGGAAGGTTATCT; and reverse,
dGTAACGCTACAGGGTATGGAACA.
The c-MYB probe was labeled with reporter dye:
6-carboxyﬂuorescein (FAM) at the 50 end and Black Hole
quencher at 30 end. The probe sequence was dTCAAAAG-
CCAGCCAGCCAGCAGTG.
The GAPDH was employed as a reporter gene for QRT-
PCR. The product was obtained with the following primers:
forward, dGACAGTCAGCCGCATCTTCTT; and reverse,
dCCAATACGACCAAATCCGTTGAC.
The GAPDH probe was labeled with reporter dye:
6-carboxyﬂuorescein (FAM) at 50 end and Black Hole
quencher at 30 end.
The probe sequence was dCGTCGCCAGCCGAGCCA-
CATCG.
All reactions were performed in triplicates with 1 mlo f
cDNA. The volume of reaction mixture was 15 ml. The reac-
tion mixturewas pre-incubated at50 Cfor 2min. PCR cycling
conditions were as follows: denaturation 95 C for 10 min,
followed by 39 cycles 92 C for 15 s, 60 C for 45 s.
Analysis of QRT-PCR data was based on comparison
of the target transcript PCR signal in a treatment group
to signal measured in an untreated control. Analysis was
done using the 2
 DDCT method as described by Levak and
Schmittgen (31).
Western blotting
Controls (untreated cells and Mock nucleofected cells, i.e. in
the absence of ODN) and cells nucleofected with ODN were
harvested, washed twice in PBS and then pelleted. The pellet
was dissolved in triple-lysis buffer composed of 50 mM Tris,
150 mM NaCl, 0.02% sodium azide, 0.1% SDS and 1% Igepal
(Sigma, St Louis), and then incubated for 30 min on ice with
vortexing every 10 min. The lysate was then spun at maximum
speed in a microfuge at 4 C for 15 min. The extracted cell
supernatant was used for western blot analysis.
Protein concentration was determined by Bradford protein
assay (BioRad). A total amount of 100 mg protein extract was
resolved on 10% polyacrylamide gel (150 V, 60 min) then
transferred on to PVDF membrane (25 V, 60 min). Condensed
milk (5%) was used as blocking solution. The membrane
was incubated overnight at 4 C with primary mouse antibody
against c-MYB clone 1-1 (Upstate, Lake Placid) at 1:1000
dilution. After incubation the membrane was washed three
times in TBS-T buffer and probed with secondary, HRP
conjugated anti-mouse antibody (Amersham Biosciences,
Piscataway) at dilution 1:1000 for 1 h at room temperature.
Blots were developed using enhanced chemiluminescence
western blotting detection kit ECL+ (Amersham Biosciences).
Membrane was then stripped with Re-blot stripping
solution (Chemicon, Temecula) and incubated with antibody
against b-actin clone AC –15 (Sigma) in dilution 1:3000.
Slot blotting
Control cells, and cells transfected with 5 mg of PS-DNA,
or PS-20F-ANA–DNA antisense were harvested at 5 min,
and 24, 72 and 96 h post nucleofection, washed twice with
PBS and pelleted. Cell pellets were then lysed in 200 mlo f
lysis buffer (50 mM HEPES, pH 7.5; 85 mM KCl and 0.5%
IGEPAL) for 20 min on ice. After lysis, cells were homo-
genized using a 1 ml dounce homogenizer (cells were dounce
50times),andcentrifugedfor10minat5000r.p.m.(6000·g).
The supernatant was removed, and put into a clean tube. The
cell pellet was resuspended in 120 ml of DEPC water. Both,
supernatant and pellet were used for slot blotting.
Sampleswere mixedwith NaOH (0.4Mﬁnal concentration)
and EDTA (10 mM ﬁnal concentration) to denature DNA,
and heated for 10 min at 100 C. The samples were then
applied to a pre-hydrated Zeta-Probe membrane (BioRad)
using a Bio-Dot SF Microﬁltration Apparatus (BioRad).
After sample ﬁltration, 500 ml of 0.4 M NaOH was added
to each sample-well and aspirated through, until the wells
were empty. The blotted membrane was then removed from
the apparatus and air-dried. The DNA in the ﬁltrate was
UV cross-linked to the membrane. The membrane was pre-
hybridized by incubation with hybridization solution (1 mM
EDTA, 7% SDS, 0.5 M NaHPO4, pH 7.2) for 30 min at 65 C.
After the pre-hybridization, radiolabeled probe was added, and
the membrane was incubated at 65 C for 12 h. Next, the
membrane was washed twice with buffer containing 0.2%
SSC and 0.2% SDS. It was then autoradiographed for 6 h
at  80 C.
Table 1. Sequences of ODNs employed in this study
Name Sequence
MOH1 50-CAAcgtTTCggaCCGtatTTC-30
MOH2 50-CAACGTTtcggaccGTATTTC-30
MOH10 50-CGTTTCGgaccgtaTTTCTGT-30
Gapmer control 50-ATATCCttgtcgTATCCC-30
Altimer control 50-ATAtccTTGtcgTATccc-30
PS-DNA 321 as dccaacgtttcggaccgtatt
PS-DNA control dgaatgtgacatttcgacacg
All nucleotides linked by phosphorothioate bridges. Upper case letters,
20F-ANA modified nucleotides. Lower case letters, unmodified nucleotides.
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transfected into the cells, was radiolabeled with T4 polynuc-
leotide kinase (New England Bio Labs, Beverly) and P-32
gamma ATP 0.075 mCi (Amersham Biosciences). To purify
the probe, Quick Spin (TE) Columns G-25 sephadex (Roche
Diagnostics, Indianapolis) were used.
RESULTS
Gene silencing effect of PS-20F-ANA–DNA chimeras
To evaluate the ability of PS-20F-ANA–DNA chimeras to
silence gene expression we employed a previously described,
well-established model system in which the human c-MYB
gene’s mRNA is targeted in K562 leukemia cells (10).
Cells of this line express c-Myb protein at high levels,
and their proliferation is c-MYB dependent. The 20F-ANA
modiﬁed sequences were directed to a region of the c-MYB
mRNA that was identiﬁed previously as being accessible
for hybridization (9). Efﬁciency of silencing was com-
pared with a PS-DNA that had been shown previously to
silence c-MYB expression with high efﬁciency (10). Three
PS-20F-ANA–DNA chimeras, namely, MOH1, MOH2 and
MOH10 were evaluated. The sequences of these compounds
are shown in Table 1. MOH1 and MOH2 were targeted to the
identical mRNA sequence, while MOH10 was targeted to the
same region but shifted 3 bases downstream. The 20F-ANA
modiﬁcations were introduced into the 21mer AS sequences
as either triplets alternating with unmodiﬁed nucleosides
(‘altimer,’ e.g. MOH1) (19), or as 7mer 20F-ANA modiﬁed
sequences ﬂanking a 7mer core of unmodiﬁed nucleosides
(‘gapmers’ e.g. MOH2 and MOH10) (11). Control altimer
and gapmer sequences were included in each assay.
In our ﬁrst series of experiments, we directly compared
the silencing efﬁcacy of PS-20F-ANA–DNA chimeras with
natural sugar PS DNA. ON (5 mg) were transfected into
K562 cells using an Amaxa device as we have reported pre-
viously (10). After 24 h, cells were harvested for extrac-
tion of mRNA and protein, which were measured using
QRT-PCR and western blotting, respectively. Results were
compared with untreated (Figure 2) or mock-transfected
cells (Figure 3) whose levels of c-MYB mRNA and protein
were arbitrarily set at 100%. MOH1 and MOH2 inhibited
c-MYB mRNA expression by 90 and 84%, respectively,
compared with the untreated control (Figure 2). Under
these conditions, the PS-DNA appeared to be somewhat
Figure 2. (A) Quantitative real-time PCR (QRT-PCR) assay performed on RNA isolated from K562 cells transfected with PS-20F-ANA and PS-DNA molecules.
Data are presented as a function of c-MYB mRNA copies relative to GAPDH mRNA. Mock (control) cells were subjected to nucleoporation, but in the absence
of DNA. (B) c-Myb protein western blot analysis performed on cell lysate obtained from K562 cells transfected with PS-20F-ANA and PS-DNA molecules.
Real-time PCR and western blot were performed 24 h post nucleofection.
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control. Neither the mock transfection procedure, nor treat-
ment with any of the control ON resulted in inhibition >16%
(Gapmer Control sequence) and all others actually had no
effect at all or slightly stimulated the expression level of
the target mRNA.The mRNAresults were accuratelyreﬂected
in the western blots (Figure 2). The MOH10 sequence
also performed well in comparison with the PS DNA. Each
ofthese compounds suppressedc-MYBmRNAby77 and81%,
respectively, in this series of experiments (Figure 3). There-
fore, the 20F-ANA modiﬁcation was compatible with efﬁcient
gene silencing but at the conclusion of these experiments
it was unclear if these molecules would be of greater utility
than unmodiﬁed PS-DNA for this purpose.
Pharmacodynamic comparison of PS-20F-ANA
chimera with PS-DNA
To address the issue of practical advantage in employing
20F-ANA modiﬁed ON, we investigated the kinetics of
knockdown and dose response of 20F-ANA versus unmodiﬁed
ON. The kinetics of silencing was investigated by analysing
c-MYB mRNA and protein levels at 72, 96 and 120 h post
transfection of 5 mg of ON (Figure 4A–C, respectively). At
72 h, MOH1, MOH2 and MOH10 treated cells had c-MYB
levels 22, 35 and 7%, respectively, of mock-transfected cells.
In marked contrast, cells treated with the AS PS-DNA
expressed levels of c-MYB mRNA and protein equivalent
to or greater than control ON treated cells. MOH1 and
MOH10 continued to be highly effective at 96 h as well
with  85% ‘knock down’ compared with mock controls.
For unclear reasons, activity of the MOH2 gapmer was lost
at 96 h. However, by 120 h, all the 20F-ANA modiﬁed ON
had also lost activity.
We also examined the potency of the 20F-ANA chimeras
compared with the unmodiﬁed PS-DNA. In dose ﬁnding
experiments of the type just described, we found that 1 mg
of PS-20F-ANA chimeras, or just 20% of the dose employed
in the initial electroporation experiments, was still able to
induce very effective silencing of the c-MYB mRNA target
Figure 3. (A) QRT-PCR assay performed on RNA isolated from K562 cells transfected with 20F-ANA and PS-DNA molecules.Data are presented as a function of
c-MYB mRNA copies relative to GAPDH RNA. Mock (control) cells were subjected to nucleoporation, but in the absence of ODN. MOH10 antisense is designed
to target c-MYB mRNA region slightly shifted toward the 30 end compared with the MOH1 and MOH2 sequences. (B) c-Myb protein western blot analysis
performed on cell lysate obtained from K562 cells transfected with 20F-ANA and PS-DNA molecules. Real-time PCR and western blot were performed 24 h post
nucleofection.
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contrast, the PS-DNA sequence had no effect whenused at this
dose (Figure 5A). Additional dose ﬁnding experiments
(Figure 5B) revealed a rather tight dose response relationship
such that none of the molecules were effective for gene silen-
cing when electroporated at a concentration of 0.5 mg. At a
concentration of 1.5 mg MOH1 and MOH10 still gave a >70%
knockdown in mRNA expression, in contrast to the PS-DNA
321 which remained ineffective. When exposed to the various
modiﬁcations at a concentration of 2 mg MOH1 silenced
c-MYB expression by 80% compared with the mock control,
MOH10 by 70%. PS-DNA 321 began to ﬁnally show activity
at this concentration, decreasing c-MYB expression by  60%.
At 3 mg, MOH1 gave further knockdown of c-MYB ( 90%),
while MOH10 and PS-DNA 321 effected a 70% decrease in
mRNA expression. Speciﬁcity of these effects was demon-
strated by the fact that knockdown observed with any of
the control molecules never exceeded 18%. It is also important
to stress that the observed knockdowns with the 20F-ANA
molecules could not be attributed to the 20F-ANA monomers
since the control 20F-ANA molecules had little or no effect on
c-MYB gene, or MYB protein expression. The duration of
the silencing effect of the 1 mg dose of PS-20F-ANA–DNA
was also examined. At 72 h, the last time point examined,
silencing was as robust as with the 5 mg dose (data not shown).
In aggregate, all experimentaldata described above strongly
suggest that the 20F-ANA modiﬁcation signiﬁcantly improves
the effectiveness of antisense molecules when compared with
PS-DNA ONs. Nonetheless, to be certain that our ﬁndings
were not cell type speciﬁc, we examined the effectiveness
of the 20F-ANA ON modiﬁcation in other cell types as well.
When tested in Jurkat cells, another human leukemic cell line
of lymphoid, as opposed to myeloid origin, we were able to
induce inhibition of c-MYB mRNA and protein expression
with an efﬁcacy essentially identical to that observed in
K562 cells ( 80–90%; data not shown). When transfected
into normal human CD34
+ hematopoietic progenitor cells,
20F-ANA modiﬁed ON suppressed c-MYB expression  60%
compared with controls (Figure 5C). While this degree of
silencing might appear to be substantially less than that
observed in the cell lines, it is important to note that (i) the
transfection efﬁciency in normal human CD34
+ cells is only
 60–70% compared with  100% observed in the cell lines,
and (ii) c-MYB mRNA and protein are being measured on
a population basis, not at the single cell level. Accordingly,
it is highly likely that the results observed are ‘diluted’ by
the mRNA and protein contribution of non-transfected cells
and that the decreased efﬁciency of silencing is more apparent
than real.
Intracellular concentration of 20F-ANA
and DNA oligonucleotides
To gain insight into the mechanism for the enhanced dose and
kinetic response to PS-20F-ANA modiﬁed ON in comparison
with PS-DNA, we examined intracellular concentrations of
C
Figure 4. QRT-PCR and corresponding western blot analysis of c-MYB expression performed (A)7 2h( B) 96 h and (C) 120 h post nucleofection.
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Figure 5. (A) QRT-PCR and western blot analysis performed 24 h post nucleofection of cells with 1 mg of indicated ON in K562 cells. (B) QRT-PCR of c-MYB
expressioninK562cells24hafternucleofectionofONinamountsindicated.(C)c-MYBexpressioninnormalhumanCD34
+marrowcells24hpostnucleofection
with 1 mg of ON. Owing to the difficulty in obtaining CD34
+ cells for this particular experiment, scrambled control for PS-DNA not tested.
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nucleofection (Figure 6). At 5 min after transfection, the
intracellular concentrations of PS-DNA and PS-20F-ANA
modiﬁed oligos were almost identical ( 150–170 ng). How-
ever, at the later time points, the intracellular concentration of
the PS-20F-ANA chimera was considerably higher than the
corresponding PS-DNA. Even at 96 h,  70% of the starting
concentration of MOH was still detectable in the cells. No
intracellular PS-DNA was detectable in the cells at this
time point suggesting that the PS-20F-ANA chimera was
either more stable, or less subject to elimination than the
corresponding PS-DNA.
DISCUSSION
Our laboratories have had a longstanding interest in deﬁning
the structural properties of synthetic nucleic acids, and their
mRNA targets, in order to develop more effective gene
silencing agents (9,10). The Damha lab has also been actively
engaged in deﬁning the substrate speciﬁcities of RNase H
enzymes in an effort to evolve newer, more potent generations
of AS ONs (24,29,32,33). The result of these efforts has
been the development of antisense arabino (ANA) (23,32)
and 20F-ANA (Figure1) (11,19,24,26–28,32). The 20F-ANA
modiﬁcation displays substantial increases in thermal stability
when hybridized with cognate DNA or RNA as a result
of the fact that each modiﬁcation increases the Tm up to
 1.5 C/20F-ANA nt (24,26). While this increase in Tm is
not as high as that observed with ONs containing 20-
O,40-C-methylene-b-D-ribofuranoside units (’locked nucleic
acids’; DTm >+ 3 C/nt) (34), our results demonstrate that it
is clearly sufﬁcient for effective down-regulation of gene
expression.
While strength of hybridization is a factor of critical
importance in the processof mRNAtargetingand degradation,
it is clear that other parameters are also very important. One
of these is the ability of the AS ON to support cleavage of
the mRNA to which it is bound. This in turn is dependent
Figure 6. Quantification of ODN delivered to cells by nucleoporation. (A) Slot blot of ON obtained from K562 cell lysate supernatants, and residual cell pellet
5 min, as well as 24, 72 and 96 h post nucleoporation. Upper rows are PS-DNA and PS-20F-ANA–DNA (MOH10) antisense standards applied to membrane
for quantification purposes. After transfer to the membrane, the blots were probed with a radiolabeled complementary sequence. Columns show material from
untreatedcontrolcells(control),andcellsnucleoporatedwithPS-DNAandPS-20F-ANA–DNAchimera(MOH10).(B)Densitometryanalysisofslotblotcontaining
ON present in cell lysates, and remaining pellets, 5 min and 24, 72 and 96 h post nucleoporation of material. Control cells were nucleoporated in the absence
of exogenous ON.
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by endogenous RNase H. During the course of our studies, we
have discovered that ANA and 20F-ANA ONs support human
RNase H1 activity (11,23) because the arabinose sugar does
not alter the overall helical structure of the corresponding
ON/mRNA hybrid when compared with the native DNA/
RNA substrate (27,28,32). This ﬁnding is of fundamental
interest for several reasons. First, these ONs represented
the ﬁrst examples of RNase H-competent ONs that lack
2-deoxy-D-ribofuranose. Typically, chemical changes of the
sugar moiety (e.g. RNA, 20OMeRNA and LNA), alterations in
the orientation of the sugar to the base, or 20F or OH groups,
completely abolish RNase H activation (27,35). Second,
these ﬁndings enhance our understanding of the catalytic
mechanism andsubstrateselectivityofRNaseHby illustrating
how AS ON sugar stereochemistry impacts on hybrid con-
formation. In this regard, it is also very important to note
that RNaseH directed cleavage of the mRNA strand occurs
across both the 20F-ANA and DNA segments (11). This is
because 20F-ANA is a mimic of DNA (27,28), allowing the
enzyme (which recognizes only DNA/RNA hybrids) to cleave
at both 20F-ANA/RNA and DNA/RNA segments (i.e. through-
out the ON/RNA duplex). In standard 20-O-alkyl RNA gap-
mers, such cleavage can only occur across the DNA gap. Of
equal if not greater interest, we have also demonstrated that
20F-ANA directed cleavage can occur when there is but one
central DNA gap, while the 20-O-alkyl RNA gapmers require a
DNA gap of at least 8 nt (11). This could also be an important
factor contributing to the potency of 20F-ANA modiﬁed
ONs. Third, ANA and 20F-ANA ONs are resistant to endo
and exonucleases, and this resistance is further enhanced
if the FANA modiﬁed nucleosides are connected by phos-
phorothioate linkages. PS-20F-ANA, for example, are >20-
fold more stable than PS-DNA towards 30-exonuclease
hydrolysis (M. J. Damha and K. L. Min, unpublished data).
The increased stability of hybrids formed by 20F-ANA and
target RNA as well as the ability to induce RNase H degrada-
tion appears to come from conformational pre-organization
of the ﬂuorinated sugars. X-ray crystallographic data from
Fedoroff et al. (36) and Berger et al. (37) demonstrated
adoption of an O40-endo (east) sugar pucker, a conformation
that lies between the C20-endo (south) and C30-endo (north)
puckers, by 20F-ANA. Amazingly, Salazar et al. (38) demon-
stratedthatthesugaroftheDNAstrand inaDNA/RNA duplex
that is recognized by RNase H, has neither south nor north
conformation, but instead is east in type.
For all the reasons noted above then, we hypothesized that
20F-ANA modiﬁed ON could have considerable potential as
therapeutic gene silencing agents. Accordingly, we sought to
test this hypothesis by examining the efﬁcacy of 20F-ANA as
gene silencing agents in living cells, and to compare their
efﬁcacy with the chemical modiﬁcation that has been most
widely used in the clinic, namely phosphorothioated DNA
(PS-DNA). Our data clearly demonstrate the superiority
of ON bearing the 20F-ANA modiﬁcation. Gene silencing
effected by ON bearing this modiﬁcation was virtually com-
plete, lasted at least twice as long as the PS-DNA, and could
be achieved at  20% of the dose needed by PS-DNA to
accomplish a similar degree of ‘knock down’. It is important
to note again that this effect was not due to the ﬂuorinated
monomers, which might have been produced as a result of
enzymatic degradation of the parent compounds, because the
control 20F-ANA molecules never gave a similar effect. The
apparent basis for this enhanced efﬁciency was also identiﬁed,
and ascribed to the signiﬁcantly higher intracellular con-
centrations of PS-20F-ANA–DNA chimeras over the period
of observation. This phenomenon in turn was shown not to
be due to differences in delivery of the molecules into cells.
Rather, enhanced ability to activate RNase H, enhanced
resistance of these molecules to nuclease degradation and
possibly reduced export from cells in comparison with
PS-DNA were thought to be the most probable explanations.
We also speculate that these molecules may have increased
bioavailability within cells, since increasing intracellular
concentration alone does not always enhance gene silencing
ability [A. M. Gewirtz, unpublished data and Ref. (39)].
The attributes described above are clearly important with
respect to potential therapeutic utilization of the 20F-ANA
modiﬁcation. Highly efﬁcient inhibition of gene expression
is the goal of all therapeutically motivated gene silencing
strategies, and the data presented here strongly suggest that
the 20F-ANA modiﬁcation will support this objective for
several reasons. First, the 20F-ANA modiﬁcation promotes
highly efﬁcient gene silencing in living cells. Second, and
potentially of equal importance, 20F-ANA modiﬁed ON sup-
press gene expression for a prolonged period of time after
a single administration. This attribute suggests that longer
dosing intervals might be possible with ‘drugs’ bearing the
20F-ANA modiﬁcation. A prolonged interval between doses is
clearly advantageous for practitioner, staff and patient alike
in both in-patient and out-patient settings. Efﬁcient silencing
at substantially lower concentrations also implies the possib-
ility of signiﬁcant cost savings as well. Accordingly, we have
many good reasons to hypothesize that 20F-ANA modiﬁed
ON will make a signiﬁcant addition to the armamentarium
of rationally targeted anticancer drugs, and will make an
important contribution to the treatment of other diseases
where gene silencing is expected to lead to useful therapeutic
consequences.
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